Clinical Trials Browser

Active not recruiting × Pancreatic Neoplasms × Albumin-Bound Paclitaxel × Clear all

NCT04233866 2026-03-02

Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT04104672 2026-02-27

ARC-8

Phase 1 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT04241276 2026-01-07

STARPAC2

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06115499 2026-01-07

The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer

Phase 2/3 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT04396821 2025-12-17

A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors

Phase 1/2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms, Stomach Neoplasms

NCT02481635 2025-12-08

A Study of Gemcitabine/Nab-paclitaxel and Radiation Therapy Followed by Surgery in Patients With Advanced Pancreatic Cancer

Phase 1/2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT02495896 2025-11-10

Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors

Phase 1 Active not recruiting

GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Gallbladder Neoplasms, Pancreatic Neoplasms

NCT04821284 2025-11-04

Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer

Phase 1/2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT05497778 2025-10-14

A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer.

Phase 1 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT04940286 2025-10-08

Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT05669482 2025-09-02

RAMP205

Phase 1/2 Active not recruiting

Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms

NCT02340117 2025-05-30

Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT05632328 2025-05-20

AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06390059 2025-04-30

EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT05586516 2025-03-20

A Study to Assess an ATX Inhibitor (IOA-289) in Patients with Metastatic Pancreatic Cancer

Phase 1/2 Active not recruiting

Gastrointestinal

Fibrosis, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

NCT03252808 2024-12-09

Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients with Unresectable Pancreatic Cancer.

Phase 1 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT03678883 2024-11-07

9-ING-41 in Patients with Advanced Cancers

Phase 2 Active not recruiting

BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT04589234 2024-04-24

Saltikva for Metastatic Pancreatic Cancer

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms